LONG BEACH, Calif. / Sep 09, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) today announced it will issue its earnings release for the third quarter ending September 30, 2024, after the market closes on Wednesday, October 23, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, October 24, 2024, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 7014206. A telephonic replay of the conference call will be available through Thursday, October 31, 2024, by dialing (877) 344-7529 and entering the confirmation number, 5232318.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available shortly following the conclusion of the live broadcast.
2024 Investor Day
The Company also announced it will host its 2024 Investor Day meeting on Friday, November 8, 2024, in New York City. The publicly webcast event will begin at 9:30 a.m. Eastern Time.
In-person attendance is by invitation only. All others are invited to register for the event on the Company’s investor relations website at investors.molinahealthcare.com, or directly via the following link: Molina Investor Day Meeting 2024. A 30-day online replay of the Investor Day meeting will be available shortly following the conclusion of the live webcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
Last Trade: | US$332.38 |
Daily Change: | -3.12 -0.93 |
Daily Volume: | 1,144,828 |
Market Cap: | US$19.010B |
November 18, 2024 October 23, 2024 October 16, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load